(VIANEWS) – Shares of MEDINCELL (CAC 40: MEDCL.PA) dropped by a staggering 10.73% to €8.32 at 14:06 EST on Thursday, following the last session’s downward trend. CAC 40 is falling 0.93% to €7,335.18, following the last session’s upward trend. This seems, up to now, a somewhat negative trend trading session today.
MEDINCELL’s last close was €9.32, 10.04% below its 52-week high of €10.36.
About MEDINCELL
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-1.2.
Revenue Growth
Year-on-year quarterly revenue growth grew by 276.2%, now sitting on 8.52M for the twelve trailing months.
Volatility
MEDINCELL’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.66%, a negative 0.19%, and a positive 2.72%.
MEDINCELL’s highest amplitude of average volatility was 9.96% (last week), 3.24% (last month), and 2.72% (last quarter).
More news about MEDINCELL (MEDCL.PA).
